The High Frequency of PIK3CA Mutations in Iranian Breast Cancer Patients

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol. 2009;20:556–563.
   PubMed Web of Science ®Google Scholar
• Enayatrad M, Amoori N, Salehiniya H. Epidemiology and trends in breast cancer mortality in Iran. Iran J Public Health. 2015;44:430–431.
   PubMed Web of Science ®Google Scholar
• Samuels Y, Waldman T. Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol. 2010;347:21–41.
   PubMed Web of Science ®Google Scholar
• Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo Z, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554.
   PubMed Web of Science ®Google Scholar
• Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004;64:7678–7681.
   PubMed Web of Science ®Google Scholar
• Maruyama N, Miyoshi Y, Taguchi T, Tamaki Y, Monden M, Noguchi S. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res. 2007;13:408–414.
   PubMed Web of Science ®Google Scholar
• Barbareschi M, Buttitta F, Felicioni L, Cotrupi S, Barassi F, Grammastro M, et al. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res. 2007;13:6064–6069.
   PubMed Web of Science ®Google Scholar
• Kalinsky K, Jacks LM, Heguy A, Ptail S, Drobnjak M, Bhanot UK, et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res. 2009;15:5049–5059.
   PubMed Web of Science ®Google Scholar
• Bozhanov SS, Angelova SG, Krasteva ME, Markov TL, Christova SL, Gavrilov IG, et al. Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer. J Cancer Res ClinOncol. 2010;136:1657–1669.
   PubMed Web of Science ®Google Scholar
• Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA. 2010;107:10208–10213.
   PubMed Web of Science ®Google Scholar
• Cizkova M, Susini A, Vacher S, Cizeron-Clairac G, Andrieu C, Driouch K, et al. PIK3CA mutation impact on survival in breast cancer patients and in ERalpha, PR and ERBB2-based subgroups. Breast Cancer Res. 2012;14:R28.
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Waterfield MD. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res. 1999;253:239–254.
   PubMed Web of Science ®Google Scholar
• Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 2005;65:2554–2559.
   PubMed Web of Science ®Google Scholar
• Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA. 2005;102:802–807.
   PubMed Web of Science ®Google Scholar
• Ikenoue T, Kanai F, Hikiba Y, Obata T, Tanaka Y, Imamura J, et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res. 2005;65:4562–4567.
   PubMed Web of Science ®Google Scholar
• Qiu W, Tong GX, Turk AT, Close LG, Caruana SM, Su GH. Oncogenic PIK3CA mutation and dysregulation in human salivary duct carcinoma. Biomed Res Int. 2014;2014:810487.
   PubMed Web of Science ®Google Scholar
• Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992;22:207–219.
   PubMed Web of Science ®Google Scholar
• Bellacosa A, Etro D, Neri LM. Mutations of the PIK3CA gene in ovarian and breast cancer. Wom Oncol Rev. 2005;5(4):223--225.
   Google Scholar
• Miller TW, Rexer BN, Garrett JT, Arteaga CL. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res. 2011;13:224.
   PubMed Web of Science ®Google Scholar
• Lerma E, Catasus L, Gallardo A, Peiro G, Alonso C, Aranda I, et al. Exon 20 PIK3CA mutations decreases survival in aggressive (Her-2 positive) breast carcinomas. Virchows Arch. 2008;453(2):133–139.
   PubMed Web of Science ®Google Scholar
• Gharbi S, Faghihi M, Tavassoli M. A novel PIK3CA hotspot mutation in Isfahanian breast cancer patients. Cancer Invest. 2011;29:313–317.
   PubMed Web of Science ®Google Scholar
• Jensen JD, Knoop A, Laenkholm AV, Grausland M, Jensen MB, Santoni-Rugiu E, et al. PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Ann Oncol. 2012;23:2034–2042.
   PubMed Web of Science ®Google Scholar
• Ramirez-Ardila DE, Helmijr JC, Look MP, Lurkin I, Ruigrok-Ritstier K, Laere SV, et al. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen. Breast Cancer Res Treat. 2013;139:39–49.
   PubMed Web of Science ®Google Scholar
• Lai YL, Mau BL, Cheng WH, Chen HM, Chiu HH, Tzen CY. PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Ann Surg Oncol. 2008;15:1064–1069.
   PubMed Web of Science ®Google Scholar
• Yau C, Benz S, Vaske C, Ng S, Stuart J, Benz CC. Differential pathway activation associated with domain-specific PIK3CA mutations. Cancer Res. 2014;74:4165.
   Web of Science ®Google Scholar
• Li SY, Rong M, Grieu F, Iacopetta B. PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat. 2006;96:91–95.
   PubMed Web of Science ®Google Scholar
• Buttitta F, Felicioni L, Barassi F, Martella C, Paolizzi D, Fresu G, et al. PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. J Pathol. 2006;208:350–355.
   PubMed Web of Science ®Google Scholar
• Harle A, Lion M, Lozano N, Husson M, Harter V, Genin P, et al. Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinico-pathological criteria. Onco Rep. 2013;29:1043–1052.
   Google Scholar
• Arsenic R, Lehmann A, Budczies J, Koch I, Prinzler J, Kleine-Tabbe A, et al. Analysis of PIK3CA mutations in breast cancer subtypes. Appl Immunohistochem Mol Morphol. 2014;22:50–56.
   PubMedGoogle Scholar
• Adamczyk A, Niemiec J, Janecka A, Harazin-Lechowska A, Ambicka A, Grela-Wojewoda A, et al. Prognostic value of PIK3CA mutation status, PTEN and androgen receptor expression for metastasis-free survival in HER2+ breast cancer patients treated with trastuzumab in adjuvant setting. Pol J Pathol. 2015;66(2):133–141.
   PubMed Web of Science ®Google Scholar